Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

LuCaP prostate cancer patient-derived xenografts reflect the molecular heterogeneity of advanced disease and serve as models for evaluating cancer therapeutics [GE]

ABSTRACT: In order to advance our understanding of prostate cancer biology and identify new effective treatments we have established and characterized multiple advanced prostate cancer patient-derived xenografts that mimic well the disease in patients.

ORGANISM(S): Homo sapiens

PROVIDER: GSE93809 | GEO | 2017/01/19

SECONDARY ACCESSION(S): PRJNA362471

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

LuCaP prostate cancer patient-derived xenografts reflect the molecular heterogeneity of advanced disease and serve as models for evaluating cancer therapeutics [CGH]

Project description:In order to advance our understanding of prostate cancer biology and identify new effective treatments we have established and characterized multiple advanced prostate cancer patient-derived xenografts that mimic well the disease in patients.

2017-01-19 | GSE93812 | GEO

LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics.

Project description: Not available

| S-EPMC5354949 | biostudies-literature

LuCaP prostate cancer patient-derived xenografts reflect the molecular heterogeneity of advanced disease and serve as models for evaluating cancer therapeutics

Project description:This SuperSeries is composed of the SubSeries listed below.

2017-01-19 | GSE93808 | GEO

LuCaP prostate cancer patient-derived xenografts reflect the molecular heterogeneity of advanced disease and serve as models for evaluating cancer therapeutics

Project description:LuCaP prostate cancer patient-derived xenografts reflect the molecular heterogeneity of advanced disease and serve as models for evaluating cancer therapeutics

| PRJNA362468 | ENA

RNA seq analysis of LuCaP Prostate Cancer Patient-Derived Xenografts

Project description:We assembled a prostate xenograft interactome from a large data set with 128 RNA sequencing expression profiles generated through administration of 13 small molecule perturbagens in vivo to 5 distinct and genetically diverse LuCaP xenograft lines (LuCaP 73, LuCaP77, LuCaP 78, LuCaP 81, LuCaP 147), with half of the xenograft samples collected from hosts castrated for 1 week.

2023-01-23 | GSE184427 | GEO

Proteomics of prostate cancer patient derived xenografts

Project description:A set of 17 prostate cancer patient-derived xenografts (PDX, Lin et al 2014, Cancer research) was analyzed by mass spectrometry-based proteomics to characterize the effects of castration in vivo, and the proteome differences between NEPC and prostate adenocarcinomas.

2019-09-11 | PXD009636 | Pride

Epigenomic alterations in localized and advanced prostate cancer

Project description:Here we used Illumina NGS for high-throughput profiling of the DNA methylome in seven human benign prostate tissues, seven human primary prostate cancer and six human castration resistant prostate cancer patient samples. These data were used to profile the CpG cytosine methylation pattern at single base resolution in each sample and to determine differentially methylated cytosines and regions among samples. Enhanced Reduced Representation Bisulfite Sequencing (ERRBS, MspI,150M-bM-^@M-^S400 bp size fractions) of 20 human prostate tissues (benign prostate tissues, localized and metastatic prostate cancer)

2013-07-03 | E-GEOD-41701 | biostudies-arrayexpress

SU086 Treatment for Advanced Prostate Cancer

Project description:We tested a novel small molecule, SU086, as a therapeutic strategy for advanced prostate cancer. Proteomic analysis was performed on treated cell lines and controls to identify protein differences. Cellular thermal shift assay (CETSA) was used to determine the interaction of SU086 with proteins.

2022-04-01 | PXD030524 | Pride

Role of MITF in advanced lethal prostate cancer

Project description:Great efforts have been made to identify key molecular aberrations that sustain growth and confer resistance to androgen deprivation therapy (ADT) in advanced prostate cancer (PC), and yet PC remains a lethal disease. Recent years have witnessed the discovery of several master regulator transcription factors that enhance lethal PC aggressiveness and provide actionable targets that may improve patient survival. Here we explore the role of the microphthalmia transcription factor (MITF) in lethal prostate cancer. To identify the mechanisms through which MITF mododulates prostate cancer aggressiveness, we knock-down MITF in three prostate cancer cell lines to identify the MITF regulated effector gene network contributing to lethal prostate cancer. Methods: We compared global transcription of three prostate cancer cell lines transduced with a siRNA control and 2 siRNAs targetting MITF by RNAseq. Results: RNA-seq of MITF knockdown prostate cancer cells uncovered a trasncriptional network of MITF regulated genes Conclusions: MITF regulates a discrette gene network that contributes to prostate cancer aggressiveness

2023-12-22 | GSE133977 | GEO

Epigenomic alterations in localized and advanced prostate cancer

2013-07-03 | GSE41701 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data